Tags: Inflammation

announcements

Three New Grants Keep Promising Programs Forging Ahead

The Alzheimer’s Drug Discovery Foundation (ADDF) announces three new investments, all of which are for programs that the ADDF previously funded.

blog

Combination Therapy: The Right Approach for Alzheimer’s

Combination therapy will be the most effective treatment for Alzheimer’s disease. Learn why they hold such promise and why Amylyx's drug is the first such therapy we are funding. 

announcements

Innovative Alzheimer's Combination Therapy Trial Supported by New Joint Funding Initiative

We are jointly funding a new combination therapy clinical trial for Alzheimer’s disease to be conducted by Amylyx Pharmaceuticals.

announcements

18th Annual Conference on Alzheimer's Drug Discovery Showcases Non-Amyloid Research

Nearly 200 academic and industry researchers came together to share updates on innovative preclinical and clinical-stage Alzheimer’s disease research at the 18th Annual Conference on Alzheimer's Drug Discovery.

blog

Driving Innovation in Alzheimer's Therapies

At our 18th Annual Conference on Alzheimer’s Drug Discovery in Jersey City, the impact of our approach will take center stage.

blog

Inflammation, The Driver of Alzheimer's Disease?

A growing body of evidence suggests that inflammation in the brain is implicated in the development of Alzheimer's.

announcements

$4 Million in New Grants Support Several First-in-Class Dementia Treatments

We recently awarded eight new grants totaling over $4 million to advance treatments for Alzheimer’s and related dementias. Several of the awards support new approaches to treating these diseases.

blog

Top Five Alzheimer’s Advances in 2016

In 2016, we made great progress toward finding drugs to prevent and treat Alzheimer’s, as our top five advances demonstrate.

announcements

$2.5 Million in New Grants Advance Clinical Trials of Alzheimer’s Treatments

We awarded three new grants in November and December, totaling nearly $2.5 million. The grants represent our commitment to advancing the most promising drugs to clinical trials, the final stages of drug development.  

announcements

New Clinical Trial Will Test Cancer Drug as Alzheimer's Treatment

Dr. Howard Fillit, the ADDF's Founding Executive Director and Chief Science Officer, says: "The ADDF is proud to support a clinical trial that holds such promise for Alzheimer's patients. This funding is part of our wider initiative to use the knowledge gained from cancer research to advance effective treatments for Alzheimer's."